Peter H. Andersen
Dr Peter Høngaard Andersen has more than 25 years of experience in drug discovery and development.
Peter spent 14 years at Novo Nordisk (working across CNS, neuroendocrinology, women health, and type 2 diabetes) and 15 years at Lundbeck CNS (working in drug discovery and early development). He has been involved in the discovery and development of several drugs on the market (including Norditropine Simplexx®, Victoza®, Trintellix/Brintellix® and Cipralex®), and has founded and co-founded several biotech companies such as Acadia Pharmaceuticals, Zealand Pharma, Glycom, Serendex, Epitherapeutics, Prexton Pharmaceuticals.
Peter was involved in Innovative Medicines Initiative (IMI) from its inception in 2003, chairing the industry side of IMI from 2009 to 2014. Peter also founded Innovation Fund Denmark in 2014, where he served as Managing Director until May 2019.
Peter is currently Chairman of the Board of Directors of Scandion Oncology A/S, Chairman of the Innovation Board for the Association of Danish Regions, and Chairman of the InnoExplorer panel at Innovation Fund Denmark. He is also Board member of Immunovia AB, and a member of the advisory board for Eir Ventures.
Peter holds a Bachelor’s degree in Chemistry and MSc in Biochemistry from the University of Copenhagen, and is a Doctor of Medicine.